Amedisys, Inc. (AMED) Reports Mixed Q3 Results; Cuts FY11 EPS Guidance; Announces Strategic Alignment, Mgmt Changes
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Join SI Premium – FREE
Amedisys, Inc. (NASDAQ: AMED) reported Q3 EPS of $0.36, vs. the analyst estimate of $0.50. Revenue for the quarter came in at $374.9 million versus the consensus estimate of $372.06 million.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- InspireMD (NSPR) Tops Q2 EPS by 1c
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Management Changes, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
